trending Market Intelligence /marketintelligence/en/news-insights/trending/6EhX_Z685tfMUwZQBOkssQ2 content esgSubNav
In This List

Biofrontera acquires dermatology company Cutanea for $1

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Biofrontera acquires dermatology company Cutanea for $1

Biofrontera AG will acquire U.S.-based dermatology company Cutanea Life Sciences Inc., which markets an acne treatment and other products, for $1.

Germany's Biofrontera will acquire the company through a subsidiary from Japan's Maruho Co. Ltd., which holds a 20% stake in Biofrontera, according to a March 25 press release.

Besides the acne treatment Aktipak, Cutanea in November 2018 launched Xepi, a treatment for a bacterial skin infection called impetigo.

Maruho plans to provide up to $7.3 million in startup funds for the development of Biofrontera's drug candidates through the transaction. Profits from Aktipak and Xepi will later be split between Maruho and Biofrontera.